Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q2 2019 · 10-Q
Revenue$42.78K$42.78K−87.9% vs Q2 2018 Net Income-$218.39K-$218.39KN/M vs Q2 2018 EPS Diluted-$0.01-$0.01N/M vs Q2 2018 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flowderived-$681,065N/M Free Cash Flowderived-$678,227N/M Margins · derivedGross margin-12.7%−71.3 pt vs Q2 2018
Operating margin-720.4%−739.7 pt vs Q2 2018
Net margin-510.6%−529.6 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 14, 2019 · 45 d after period end